ADAM-20 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human ADAM-20 (UniProt O43506) expressed in HEK293 cells. Suited for metalloproteinase activity assays, inhibitor profiling, and antibody validation; pairs with TPB antibody RP-ADAM20.
Expression system
HEK293
Cat. #
REC-ADAM20

In stock

SKU
REC-ADAM20
$498.00

Target Overview

ADAM-20 (Disintegrin and metalloproteinase domain-containing protein 20; UniProt O43506) is a 726-amino-acid membrane-anchored metalloproteinase of the ADAM family, classified under EC 3.4.24.-. Like other ADAM-family members, it carries a prodomain, a zinc-dependent metalloproteinase catalytic domain, a disintegrin domain, a cysteine-rich region, an EGF-like domain, a transmembrane segment, and a cytoplasmic tail — a multi-domain architecture that underlies both proteolytic and cell-adhesion functions. Published evidence points to a role in sperm maturation and fertilisation, consistent with the testis-enriched expression reported for several ADAM-family members. This recombinant is produced in HEK293 mammalian cells, a system that supports the glycosylation and disulfide-bond formation characteristic of native ADAM-family ectodomains. Mammalian expression is particularly important for ADAM proteins, whose multi-domain folding and disulfide pairing are not reliably reproduced in prokaryotic hosts. Researchers use this recombinant in several contexts: as an active enzyme source for substrate-cleavage and metalloproteinase activity assays, as an antigen standard or positive-control lysate supplement in Western blot and ELISA workflows, and as an immobilised ligand or capture protein in surface plasmon resonance or biolayer interferometry studies of inhibitor binding. For antibody validation workflows, this recombinant is the matched positive-control antigen for Triple Point Biologics antibody RP-ADAM20 — researchers confirming band specificity in Western blot or antigen retrieval optimisation in IHC can use the two reagents together. Human species reactivity is validated; cross-reactivity with mouse, rat, non-human primate, and canine orthologues is predicted based on sequence conservation.

Background

ADAM-20 belongs to the ADAM (A Disintegrin And Metalloproteinase) superfamily, a class of zinc-dependent proteases that mediate ectodomain shedding, cell-matrix remodelling, and cell-cell adhesion events. The family shares a conserved catalytic motif (HEXXHXXGXXH) that coordinates a catalytic zinc ion. ADAM-20 is most highly expressed in testis, and functional data suggest a role in sperm maturation and the sperm-egg fusion cascade. The clearest direct evidence for ADAM-20's biological importance in reproduction comes from human genetics. Sha et al. (2018, Oncotarget) described a rare ADAM20 variant in a Chinese male patient presenting with sperm-egg fusion disorder, providing a direct link between ADAM20 sequence variants and male infertility phenotypes. This positions ADAM-20 as a research target for studies of fertilisation mechanisms and for in vitro modelling of sperm-surface remodelling events — work for which a well-characterised recombinant antigen or enzyme source is a practical necessity. Beyond reproductive biology, ADAM-20 has appeared in broader transcriptomic and proteomic profiling studies. Tugutova et al. (2019, Asian Pacific Journal of Cancer Prevention) examined tetraspanin-associated and non-associated exosomal proteases in colorectal cancer patients, a context in which ADAM-family members have been catalogued as components of tumour-derived extracellular vesicles. The presence of ADAM proteases in exosomal fractions has raised interest in their roles in paracrine signalling and matrix remodelling in the tumour microenvironment — areas where recombinant ADAM proteins are used to establish activity baselines and validate detection reagents. ADAM-20 has also appeared in multi-gene expression analyses relevant to reproductive performance under physiological stress (Sigdel et al., 2020, Animal Genetics) and in whole-transcriptome profiling studies of pharmacological perturbation in cancer models (Chen et al., 2022, Frontiers in Oncology), reflecting its broader identification as a differentially expressed metalloproteinase across tissue and disease contexts. Across these published applications, recombinant ADAM-20 protein serves several practical roles: as an enzyme source for in vitro cleavage assays against candidate substrates, as a positive-control antigen for antibody characterisation, and as a capture reagent for binding studies. Researchers using this recombinant for antibody validation can cross-reference with Triple Point Biologics antibody RP-ADAM20, the matched antibody validated for Western blot against this target. Triple Point Biologics has produced proteinase and inhibitor antibodies since 1994, and the ADAM-20 reagent pair reflects that accumulated experience with metalloproteinase-family targets.

Applications

  • Zinc-metalloproteinase activity assay using fluorogenic peptide substrates
  • Inhibitor IC50 determination in enzyme-inhibitor titration formats
  • Antibody validation positive control — matched to Triple Point Biologics antibody RP-ADAM20 for Western blot band confirmation
  • ELISA capture antigen or standard curve protein for anti-ADAM20 immunoassay development
  • Sperm-surface remodelling in vitro modelling: substrate identification by mass spectrometry
  • Surface plasmon resonance or biolayer interferometry binding studies with candidate ADAM-20 inhibitors or binding partners
  • Exosomal protease profiling: recombinant standard for quantification in vesicle proteomics workflows

References

  1. Sha YW et al. Sperm-egg fusion disorder in a Chinese male patient was associated with a rare ADAM20 variant. Oncotarget. 2018. doi:10.18632/oncotarget.23331 PMID: 29416755
  2. Tugutova EA et al. Relation between Tetraspanin-Associated and Tetraspanin-Non-Associated Exosomal Proteases and Metabolic Syndrome in Colorectal Cancer Patients. Asian Pac J Cancer Prev. 2019. doi:10.31557/APJCP.2019.20.3.809 PMID: 30909692
  3. Sigdel A et al. Genetic dissection of reproductive performance of dairy cows under heat stress. Anim Genet. 2020. doi:10.1111/age.12943 PMID: 32363588
  4. Chen N et al. Integrated Whole-Transcriptome Profiling and Bioinformatics Analysis of the Polypharmacological Effects of Ganoderic Acid Me in Colorectal Cancer Treatment. Front Oncol. 2022. doi:10.3389/fonc.2022.833375 PMID: 35574354
  5. Swierkowska J et al. Decreased Levels of DNA Methylation in the PCDHA Gene Cluster as a Risk Factor for Early-Onset High Myopia in Young Children. Invest Ophthalmol Vis Sci. 2022. doi:10.1167/iovs.63.9.31 PMID: 36036911

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAM-20 on SDS-PAGE or Western blot?

The unprocessed ADAM-20 polypeptide (UniProt O43506) runs at a predicted ~83 kDa based on 726 amino acids, but the HEK293-expressed recombinant carries N-linked glycosylation characteristic of native ADAM ectodomains, so the apparent MW on reducing SDS-PAGE typically shifts to approximately 90–100 kDa. Under non-reducing conditions, intramolecular disulfide bonds in the cysteine-rich and disintegrin domains can cause anomalous migration. Always confirm your positive-control band position against a prestained ladder in the 90–110 kDa range when using this recombinant.

Is this recombinant ADAM-20 the full-length protein or a processed ectodomain fragment?

This recombinant corresponds to the ADAM-20 ectodomain — the prodomain through the EGF-like domain — expressed in HEK293 cells and secreted into conditioned medium. The transmembrane segment and cytoplasmic tail are excluded to permit secretion and purification. The prodomain may be auto-processed during expression, yielding the mature, active metalloproteinase form; lot-specific processing status is documented in each Certificate of Analysis. If your application requires the cytoplasmic tail epitope, this construct is not appropriate.

What substrates can I use to measure ADAM-20 proteolytic activity in a fluorescence assay?

ADAM-20 is a zinc-dependent metalloproteinase (EC 3.4.24.-) with substrate preferences broadly similar to other ADAM family members. A quenched fluorescent peptide such as Mca-KPLGL-Dpa-AR-NH2 or the generic ADAM substrate Mca-PLAQAV-Dpa-RSSSR-NH2 can serve as starting points for activity assays. Reactions should be run at 37 °C in assay buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 5 mM CaCl2 — matching the storage buffer to minimize dilution artifacts. Confirm substrate turnover with a metalloproteinase inhibitor control such as 10 µM GM6001.

What buffer conditions are optimal for ADAM-20 recombinant activity assays and should I add extra calcium?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is formulated specifically for metalloproteinases and is compatible with direct use in activity assays after dilution. Glycerol carried over from the stock is generally tolerable at final concentrations below 1%. Do not reduce CaCl2 below 1 mM in the assay; calcium is required for metalloproteinase domain stability. Avoid EDTA or EGTA-containing buffers, which will chelate zinc and calcium and abolish activity. Zinc supplementation (1–10 µM ZnCl2) can improve activity if your diluent is metal-depleted.

What starting concentration of recombinant ADAM-20 should I use for an enzyme activity titration experiment?

For an initial activity titration, a useful starting range is 50–500 ng/mL (roughly 0.5–5 nM based on ~100 kDa apparent MW) in assay buffer with a fluorogenic peptide substrate at 10–50 µM. Titrate enzyme concentration while holding substrate constant to confirm linearity of signal over the first 30–60 minutes. At concentrations above 1 µg/mL, substrate depletion can become significant with sensitive peptides. For inhibitor IC50 determinations, fix enzyme at a concentration that gives 20–30% substrate conversion per hour to maintain assay sensitivity and avoid tight-binding artifacts.

Can I use recombinant ADAM-20 as a positive control for Western blot with the RP-ADAM20 rabbit polyclonal antibody?

Yes — this is one of the primary intended uses for REC-ADAM20. The matched antibody RP-ADAM20 (see /anti-adam-20-rabbit-polyclonal-antibody) was raised and validated against the same ADAM-20 ectodomain represented in this recombinant, so band recognition is assured. Load 20–50 ng of recombinant protein per lane alongside your cell or tissue lysates; this amount gives a clean, non-saturated signal at typical RP-ADAM20 dilutions. Using the recombinant as a positive control simultaneously confirms antibody performance and establishes the expected migration position in your specific gel system.

How much recombinant ADAM-20 should I load for a Western blot positive control and what antibody dilution works best?

Load 20–50 ng of REC-ADAM20 per lane for a standard positive control. At this amount, the RP-ADAM20 rabbit polyclonal antibody (SKU: RP-ADAM20) reliably detects a band in the 90–100 kDa region under standard reducing SDS-PAGE conditions. A primary antibody dilution of 1:500–1:2000 in 5% non-fat milk or BSA in TBST is a practical starting range; optimize based on your detection system and secondary antibody. ECL detection on a 10–12% polyacrylamide gel generally provides the cleanest resolution in this MW window.

How should I store recombinant ADAM-20 after receipt and how long is it stable once thawed?

Upon receipt, transfer REC-ADAM20 immediately to -20 °C. The product is supplied in single-use aliquots to eliminate repeated freeze-thaw cycles, which degrade metalloproteinase activity by disrupting zinc coordination in the catalytic domain. Once thawed, keep on ice and use within 4–8 hours; do not refreeze. For dilutions prepared in assay buffer, stability drops more rapidly — prepare working dilutions fresh on the day of use. Under recommended storage conditions, activity is maintained for at least 12 months from the date of manufacture, as stated on the Certificate of Analysis.

Validation imagery coming soon

Western blot validation figures for REC-ADAM20 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →